Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Antithrombotics in stable CAD and AF
Author(s): Massimo Grimaldi , Bianca Rocca Added: 3 months ago

Prevention & Chronic Conditions

Anticoagulation
Combined Antithrombotic Regimens and the OPTIMA-AF trial
Author(s): Alberto Alperi , Paula Antuña , Juan Rondan , et al Added: 3 months ago

Intervention

Anticoagulation
NOAC Monotherapy Noninferior to Combo Therapy Post-DES
Added: 3 months ago Source:  Arrhythmia Academy
In atrial fibrillation (AF) patients post one-year drug-eluting stent (DES) implantation, non–vitamin K antagonist oral anticoagulant (NOAC) was shown to be noninferior to NOAC plus clopidogrel combination therapy.¹ Current guidelines recommend NOAC monotherapy in this patient population, but supporting evidence has been limited.²MethodologyThe ADAPT AF-DES trial was a multicenter, randomised,… View more

Anticoagulation

Electrophysiology & Arrhythmia
Lipid-lowering Therapies and Lp(a)
Author(s): Stephen Nicholls , Adam J Nelson Added: 1 month ago

Prevention & Chronic Conditions
ESC 24: EPIC-CAD: Edoxaban vs Dual Antiplatelet Therapy in AF & CAD
Author(s): Gi-Byoung Nam , Min Soo Cho Added: 1 year ago
ESC Congress 2024 — Edoxaban monotherapy significantly improves outcomes in high-risk patients with CAD and atrial fibrillation.Investigators, Dr Gi-Byoung Nam (Ulsan University Hospital, Ulsan, SK) and Dr Min Soo Cho (Asan Medical Center, Seoul, SK) join us to discuss the key findings from the EPIC-CAD trial (NCT03718559).This Korean multi-centre, open-labelled, randomised controlled study… View more

Anticoagulation

Electrophysiology & Arrhythmia
Heart Failure in 2026: Practical Therapy Lessons From ACC.26
Author(s): Felipe Martínez Added: 2 months ago
ACC.26 - In this expert interview filmed at ACC.26 in New Orleans, Prof. Felipe Martínez discusses how late-breaking heart failure data are reshaping contemporary pharmacological management. The conversation focuses on new spironolactone results, advanced hemodynamic strategies in HFpEF, and the expanding role of cardiometabolic therapies, including GLP‑1 receptor agonists, in optimising outcomes… View more

Heart Failure
AHA 25: Beta-Blocker Therapy Post MI in Patients with Preserved LVEF
Author(s): Anna Meta Dyrvig Kristensen Added: 6 months ago
AHA Scientific Sessions 2025 – Dr Anna Meta Dyrvig Kristensen (Copenhagen University Hospital, Bispebjerg and Frederiksberg, DK) presents an individual patient data meta-analysis examining beta-blocker therapy after myocardial infarction in patients with preserved left ventricular ejection fraction.This comprehensive meta-analysis pooled individual patient data from five randomized controlled… View more

Heart Failure
AHA 25: CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3
Author(s): Stephen Nicholls Added: 7 months ago
AHA Scientific Sessions 2025 - Phase 1 results show the CRISPR-Cas9 gene editing therapy is a safe treatment option targeting ANGPTL3 in patients with lipid disorders.Prof Stephen Nicholls (Monash Victorian Heart Institute, Clayton, AU) joins us to share results from a first-in-human phase 1 trial investigating a one-time infusion of CTX310, a CRISPR-Cas9 gene editing therapy, at different doses… View more

Prevention & Chronic Conditions
Left Main Disease: The Last Frontier for Medical Therapy in Stable CAD?
Author(s): Armin Arbab-Zadeh , Michelle Graham , Hector M Garcia-Garcia , et al Added: 8 months ago

Intervention

Prevention & Chronic Conditions
ESC 25: Lifetime Benefits of Combination Therapy in HFpEF
Author(s): Muthiah Vaduganathan Added: 9 months ago
ESC Congress 2025 - Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, Boston, US) joins us to discuss findings from a trial investigating the lifetime benefits of combination therapy for patients with HFpEF by looking at individual level data from DELIVER, FINEARTS-HF and PARAGON-HF trials.Interview Questions:1. What is the reasoning behind the trial?2. What was the study design and patient… View more

Heart Failure